杜比實驗室 DLB 深 滬
已收盤 12-24 16:00:00 美东时间
66.18
+0.190
+0.29%
華盛通- 最 高66.33
- 今 開65.83
- 成交量 32.46万股
- 最 低 65.55
- 昨 收 65.99
- 總市值 63.43亿
- 52周最高 88.31
- 市盈率 靜 25.30
- 換手率 0.34%
- 52周最低 63.6619
- 委 比 5.71%
- 總股本 9584.42万
- 歷史最高 99.34
- 量 比 0.39
- 振 幅 1.18%
- 歷史最低 16.14
- 每 手 1
- 風險率 5.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
BAY AREA HOST COMMITTEE AND DOLBY PARTNER TO DELIVER IMMERSIVE FAN EXPERIENCES
During the Week of Football's Biggest Game, Dolby will Showcase the Future of Live Sports and Real-time Streaming Powered by Dolby Vision, Dolby Atmos and Dolby OptiView MOUNTAIN VIEW, Calif...
11-20 00:00
Rosenblatt Maintains Buy on Dolby Laboratories, Lowers Price Target to $85
Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:DLB) with a Buy and lowers the price target from $95 to $85.
11-19 21:18
Dolby Laboratories Sees Q1 GAAP EPS $0.39-$0.54 vs $0.86 Est
Dolby Laboratories (NYSE:DLB) is looking for Q1 GAAP EPS of $0.39-$0.54 vs $0.86 analyst estimate..
11-19 05:18
Dolby Laboratories Q4 Adj. EPS $0.99 Beats $0.70 Estimate, Sales $307.024M Beat $304.695M Estimate
Dolby Laboratories (NYSE:DLB) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.70 by 41.43 percent. This is a 22.22 percent increase over earnings of $0.81 per share from the
11-19 05:16
12 Information Technology Stocks Moving In Tuesday's After-Market Session
Gainers Data I/O (NASDAQ:DAIO) shares increased by 14.1% to $2.84 during Tuesd...
11-19 05:06
Earnings Scheduled For November 18, 2025
Companies Reporting Before The Bell • Oaktree Specialty Lending (NASDAQ:OCSL) i...
11-18 19:11
Enhancing HDR On Instagram For iOS With Dolby Vision
https://engineering.fb.com/2025/11/17/ios/enhancing-hdr-on-instagram-for-ios-with-dolby-vision/
11-18 03:13
Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284 At 25th Annual Lymphoma, Leukemia & Myeloma Congress
AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.A novel differentiated synthetic
10-28 20:51
浮“光”跃金：探寻OCS投资价值与方向
（来源：东北通信科技最前沿） 报告摘要： OCS光交换是一种无需光电/电光（O/E/O）转换，直接实现光信号在光纤端口间切换的技术。OCS原理是直接...
10-23 12:06
